Citrin deficiency: Does the reactivation of liver aralar-1 come into play and promote HCC development?
Acetyl Coenzyme A
/ metabolism
Amino Acid Transport Systems, Acidic
/ metabolism
Animals
Antiporters
/ metabolism
Calcium-Binding Proteins
/ deficiency
Carcinoma, Hepatocellular
/ etiology
Humans
Liver Neoplasms
/ etiology
Mitochondrial Membrane Transport Proteins
/ metabolism
NAD
/ metabolism
Organic Anion Transporters
/ deficiency
Triglycerides
/ metabolism
Aralar-1
Citrate-malate shuttle
Citrin
Citrin deficiency
Cytosolic NADH redox State
Gene re-activation
Gene redundancy
Hepatocellular carcinoma
Histone acetylation
Malate-aspartate shuttle
Mitochondrial solute carriers
SLC25A1
SLC25A12
SLC25A13
Journal
Biochimie
ISSN: 1638-6183
Titre abrégé: Biochimie
Pays: France
ID NLM: 1264604
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
04
05
2021
revised:
25
06
2021
accepted:
30
06
2021
pubmed:
7
7
2021
medline:
8
2
2022
entrez:
6
7
2021
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) is a longstanding issue in clinical practice and metabolic research. New clues in better understanding the pathogenesis of HCC might relate to the metabolic context in patients with citrin (aspartate-glutamate carrier 1) deficiency (CD). Because citrin-deficient liver (CDL) is subject to HCC, it represents a unique metabolic model to highlight the mechanisms of HCC promotion, offering different angles of study than the classical metabolic syndrome/obesity/non-alcoholic fatty liver disease (NAFLD)/HCC study axis. In turn, the metabolic features of HCC could shed light on the pathogenesis of CDL. Among these, HCC-induced re-activation of aralar-1 (aspartate-glutamate carrier 2), physiologically not expressed in the adult liver, might take place in CDL, so gene redundancy for mitochondrial aspartate-glutamate carriers would be exploited by the CDL. This proposed (aralar-1 re-activation) and known (citrate/malate cycle) adaptive mechanisms may substitute for the impaired function in CD and are consistent with the clinical remission stage of CD and CD improvement by medium-chain triglycerides (MCT). However, these metabolic adaptive benefits could also promote HCC development. In CD, as a result of PPARα down-regulation, liver mitochondrial fatty acid-derived acetyl-CoA would, like glucose-derived acetyl-CoA, be used for lipid anabolism and fuel nuclear acetylation events which might trigger aralar-1 re-activation as seen in non-CD HCC. A brief account of these metabolic events which might lead to aralar-1 re-activation in CDL is here given. Consistency of this account for CDL events further relies on the protective roles of PPARα and inhibition of mitochondrial and plasma membrane citrate transporters in non-CD HCC.
Identifiants
pubmed: 34228977
pii: S0300-9084(21)00172-3
doi: 10.1016/j.biochi.2021.06.018
pii:
doi:
Substances chimiques
Amino Acid Transport Systems, Acidic
0
Antiporters
0
Calcium-Binding Proteins
0
Mitochondrial Membrane Transport Proteins
0
Organic Anion Transporters
0
SLC25A12 protein, human
0
Triglycerides
0
aspartate-glutamate carrier
0
NAD
0U46U6E8UK
citrin
1340-08-5
Acetyl Coenzyme A
72-89-9
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
20-23Informations de copyright
Copyright © 2021 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest None.